Troponin measurements during drug development—considerations for monitoring and management of potential cardiotoxicity-Reference-Cited by-同舟云学术

Troponin measurements during drug development—considerations for monitoring and management of potential cardiotoxicity

Published:2011-07 Issue:1 Volume:162 Page:64-73
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Newby L. Kristin,Rodriguez Ignacio,Finkle John,Becker Richard C.,Hicks Karen A.,Hausner Elizabeth,Chesler Ruth,Harper Courtney,Targum Shari,Berridge Brian R.,Lewis Eric,Walker Dana B.,Dollery Colin,Turner J. Rick,Krucoff Mitchell W.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference39 articles.

1. Universal definition of myocardial infarction;Thygesen;J Am Coll Cardiol,2007

2. Troponin; the biomarker of choice for the detection of cardiac injury;Baubuin;CMAJ,2005

3. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes;Antman;N Engl J Med,1996

4. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications;Kociol;J Am Coll Cardiol,2010

5. Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolism;Mehta;Am Heart J,2003

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk and Management of Patients with Cancer and Heart Disease;Cardiology and Therapy;2023-02-09

2. Potential roles of 4HNE-adducted protein in serum extracellular vesicles as an early indicator of oxidative response against doxorubicin-induced cardiomyopathy in rats;Current Research in Toxicology;2023

3. Scientific and Regulatory Policy Committee Points to Consider: Integration of Clinical Pathology Data With Anatomic Pathology Data in Nonclinical Toxicology Studies;Veterinary Clinical Pathology;2022-08-17

4. Scientific and Regulatory Policy Committee Points to Consider: Integration of Clinical Pathology Data With Anatomic Pathology Data in Nonclinical Toxicology Studies;Toxicologic Pathology;2022-08

5. Circulating biomarkers for management of cancer therapeutics-related cardiac dysfunction;Cardiovascular Research;2022-05-31